Gillian McGovern, Associate Editor

The study shows benefits when Hecolin (HEV 239; Xiamen Innovax Biotech Co Ltd) is administered in 2 doses, rather than the typical 3-dose regimen.

Black and Native American patients were about 2 to 3 times more likely to die of cancer compared with White patients, and women younger than 50 years were affected more than male patients.

The study found that internalizing and externalizing factors, brain maturation, and decreasing volumes of brain regions were linked to eating disorders.

The authors found that humidity, cold and heat waves, and air pollution led to a higher likelihood of asthma- and chronic obstructive pulmonary disease (COPD)-related hospitalizations.

The reduction in cardiovascular end points and the increase in adverse events observed in a clinical trial were largely transportable to trial-eligible chronic kidney disease (CKD) populations from clinical practice.

Compared with chemotherapy, Dato-DXd demonstrates favorable median progression-free survival and overall survival in a phase 3 clinical trial.

The authors note that future research will observe personality changes when psilocybin is used in patients with opioid-use disorder.

Despite the reductions in hepatitis B surface antigen (HBsAg), grade 3 and 4 adverse events were not uncommon.

This is mirikizumab’s second FDA-approved indication in inflammatory bowel disease.

The test meets a critical unmet need for patients with Alzheimer disease who have not yet been undiagnosed.

Severe alcohol-associated hepatitis has limited effective pharmacological therapies, emphasizing the need for treatment options.

The findings suggest that patients with alopecia areata (AA) who also have asthma may benefit from increased clinical monitoring and earlier intervention.

Patients with methotrexate (MTX)-induced acute kidney injury treated with glucarpidase were 2.70-times more likely to have kidney recovery and recover faster.

Women living in rural are more likely to report experiencing psychological and somatic menopause symptoms compared with those in urban and suburban areas.

According to the investigators, BBO-8520 represents a first-in-class approach to treating patients with previously treated KRASG12C-mutated metastatic non-small cell lung cancer (NSCLC).

If approved, nipocalimab can treat antibody positive individuals with generalized myasthenia gravis.

Virtual appointments were also an accessible alternative to in-person visits for patients who face obstacles accessing asthma care.

The pharmacist’s role includes educating and making recommendations, collaborating with health care professionals, and observing early signs of cognitive impairment in patients during interactions.

The observational study shows a positive correlation between smoking and chronic kidney disease (CKD) whereas the analyses imply smoking-related covariates may be a factor.

The designation follows positive phase 2a trial results (NCT05104853) presented at the 2024 AASLD The Liver Meeting.

In a phase 2 trial (NCT05400226), abenacianine helps surgeons visualize tumors in lung during surgery and is safe and well-tolerated in patients.

The investigators note that the test can allow health care professionals to more accurately prescribe medication or treatments.

The tablets are indicated for treatment of adults with chronic idiopathic constipation, with further research needed to assess efficacy and safety in children.

These inequalities, which can include socioeconomic disparities, show neurological changes associated with aging and dementia.

Early diagnosis of chronic kidney disease (CKD) can help optimize treatment and manage the disease to prevent further decline.

Investigators did not report serious adverse events or deaths related to depemokimab in either of the 2 phase 3a clinical trials.

Female adolescents were at an increased risk of experiencing depression and anxiety symptoms compared with males.

Of these chemicals, 414 were found to be commonly used in plastics and consumer goods, such as food packaging and personal care products.

The approval comes after clinical trial results in which vanzacaftor/tezacaftor/deutivacaftor (Alyftrek; Vertex Pharmaceuticals) demonstrated superiority compared with elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta; Vertex Pharmaceuticals).

The approval follows positive results from the V005 (NCT03005418) clinical trial.